demonstrated that CXCL9 and CXCL10 (5000 pg/mL and 500 pg/mL as the cutoff levels, respectively) were significantly useful for the early diagnosis and therapeutic outcomes of Lymphoma‐associated hemophagocytic syndrome (LAHS). Here, CXCL9 is linked to lymphoma.